Damon Mcknight
Opioid use and its associated harms are a significant public health issue in Australia. In 2016, around 11% of Australians aged 14 and over had used opioids for non-medical purposes, with pharmaceutical opioids being more commonly used than illegal opioids. The Australian government has implemented various initiatives to address the opioid epidemic, including the establishment of the Opioid Regulatory Advisory Group (ORAG) to provide expert advice and the introduction of real-time prescription monitoring to help identify cases of overprescribing. Tasmania, known for its high rate of opioid packs sold per person, has been described as the country's epicenter for opioids. Despite these efforts, Australia's opioid problem persists, and there is a recognized need for more evidence-based interventions and access to multidisciplinary care for patients with chronic pain.
| Characteristics | Values |
|---|---|
| Government-funded pharmaceuticals | Yes |
| Comprehensive and coordinated approach to overdose prevention | No |
| National real-time prescription monitoring | Yes |
| Therapeutic Goods Administration (TGA) involvement | Yes |
| Public consultation on TGA's role | Yes |
| Regulatory actions to maintain access for chronic pain treatment | Yes |
| Consistent with actions of other medicines regulators | Yes |
| Caretaker Conventions | Yes |
| Initiatives to reduce inappropriate prescription opioids | Yes |
| Guidelines for safer pain management | Yes |
| Guidelines for patient consent and treatment agreements | Yes |
| Tasmania as the epicenter for opioids | Yes |
| High rate of opioid packs sold per person in Tasmania | 2.7 packs |
| Region with the highest number of government-subsidized opioid prescriptions | More than 110,000 per 100,000 people |
Explore related products
What You'll Learn
- The Australian government has asked the Therapeutic Goods Administration (TGA) to help tackle the opioid problem
- The TGA has implemented several initiatives to reduce inappropriate prescription opioids
- There is a need for a comprehensive and coordinated approach to overdose prevention
- The Australian government has taken steps to help healthcare providers and patients create a personalised plan to taper off opioids
- The Australian government is working to implement safer, evidence-based pain management strategies
The Australian government has asked the Therapeutic Goods Administration (TGA) to help tackle the opioid problem
The opioid epidemic in Australia has been a growing concern, with hospitalisations, emergency department admissions, and drug-induced deaths involving opioid use on the rise. In response, the Australian government has sought the assistance of the Therapeutic Goods Administration (TGA) to address this pressing issue.
The TGA, recognising the critical role of opioids in pain management, particularly for chronic and cancer-related pain, has focused on mitigating the risks associated with inappropriate use and misuse of prescription opioids. This includes ensuring that Australians can continue to access opioids appropriately and safely while reducing the potential for harm.
One key strategy has been to consult the public on potential actions and activities the TGA can undertake. This public consultation process, conducted in early 2018, aimed to gather insights and opinions on how best to tackle the opioid problem. It is worth noting that the TGA's approach aligns with actions taken by other medicines regulators, such as the Food and Drug Administration (FDA) and Health Canada, who have successfully implemented measures to curb prescription opioid misuse.
The TGA has also implemented reforms to reduce the availability of prescription opioids. For example, sponsors of impacted products must now register smaller pack sizes by submitting a Self-Assessable Request (SAR) to vary their entry on the Australian Register of Therapeutic Goods (ARTG). This reduces the quantity of opioids available with each prescription, making it harder to obtain large amounts.
Additionally, the TGA is working to ensure that patients and healthcare providers are better informed about the benefits and risks of opioid therapy. This includes encouraging the use of safer, evidence-based pain management strategies that can serve as alternatives to opioids. The TGA recognises that addressing the opioid problem requires a comprehensive and coordinated approach involving not just the government but also state and professional groups to effectively prevent overdoses and reduce harm.
Barium Deposits in Australia: Where and How Much?
You may want to see also
Explore related products
The TGA has implemented several initiatives to reduce inappropriate prescription opioids
The opioid crisis in Australia has been compared to the epidemic in the US, with Tasmania being the country's epicentre. The Australian government has been urged to take action to address the problem of opioid harm, which results in almost 150 hospitalisations and three deaths every day.
The Therapeutic Goods Administration (TGA) has implemented several initiatives to reduce inappropriate prescription opioids. In 2018, the TGA conducted a public consultation on potential actions to mitigate the risks of inappropriate use and misuse of prescription opioid products. The TGA's actions are consistent with those taken by other medicine regulators such as the FDA and Health Canada. One initiative involves the registration of smaller pack sizes, which requires impacted sponsors to submit a Self-Assessable Request (SAR) to vary their product's entry on the Australian Register of Therapeutic Goods (ARTG).
The TGA's initiatives aim to reduce the amount of inappropriate prescription opioids in the community while ensuring that patients can continue to access opioids appropriately and safely for the treatment of chronic pain, including cancer-related pain. It is recognised that opioids are essential medicines that play a critical role in pain management.
Additionally, the Australian government has implemented national guidelines for opioid therapy for chronic non-cancer pain. These guidelines recommend that patients be adequately informed about the benefits and risks of opioid therapy, including potential side effects like impaired driving ability, and that informed consent be obtained prior to initiating therapy. This may include a written treatment agreement ("opioid contract"), as required by some Australian state governments.
While the Australian government has taken steps in the right direction, the opioid problem still persists and continues to result in adverse health outcomes and unnecessary deaths. It is important to address the inappropriate use of opioids and implement strategies to reduce opioid consumption, such as safer evidence-based pain management strategies.
Australian Dollars to Pounds: 68 Equals How Much?
You may want to see also
Explore related products
There is a need for a comprehensive and coordinated approach to overdose prevention
Opioid use has become a significant issue in Australia, with around 11% of Australians aged 14 and over having used opioids for non-medical purposes. Tasmania, in particular, has the highest rate of opioid packs sold per person, with 2.7 packs each. The Australian government, in conjunction with the Therapeutic Goods Administration (TGA), has implemented several initiatives to tackle the opioid crisis. However, there is still a need for a more comprehensive and coordinated approach to overdose prevention.
One key area of focus is the inappropriate prescription of opioids. The Australian government has recognised the need to reduce the number of inappropriately prescribed opioid medications in the community. This includes ensuring that patients have access to clinically appropriate opioid medications for the treatment of chronic pain while also addressing the issue of over-prescription. The TGA has played a crucial role in this regard, with a public consultation conducted in 2018 on potential actions to mitigate the risks of inappropriate opioid use.
Despite these efforts, there has been a lack of coordination between national and state governments and professional groups in implementing effective overdose prevention strategies. Take-home naloxone formulations, for example, have been available for over five years, but uptake has been limited. Additionally, the government's initiatives have primarily focused on reducing inappropriate prescriptions without addressing the underlying reasons for over-prescription.
A comprehensive approach should include a range of measures such as improved education and access to alternative pain management strategies for patients, stricter regulations on opioid prescriptions, and increased support for individuals struggling with opioid addiction. By providing patients with information about the benefits and risks of opioid therapy, healthcare providers can empower them to make informed decisions about their opioid use.
Furthermore, addressing the social and economic factors that contribute to opioid misuse is essential. This includes ensuring equal access to healthcare services, addressing mental health issues, and providing support for individuals facing socioeconomic challenges. A coordinated response across different sectors and levels of government is necessary to effectively tackle the complex issue of opioid misuse and overdose prevention.
Join the Royal Australian Navy: Application Process Guide
You may want to see also
Explore related products
The Australian government has taken steps to help healthcare providers and patients create a personalised plan to taper off opioids
The opioid epidemic has been a pressing issue in Australia, with hospitalisations, emergency department admissions, and drug-induced deaths involving opioid use. The Australian government, in collaboration with the Therapeutic Goods Administration (TGA), has taken decisive steps to address this crisis. Recognising the critical role of opioids in pain management, the government aims to ensure appropriate and safe access to opioids while mitigating the risks of misuse.
One significant step taken by the government is the implementation of guidelines to help healthcare providers and patients create personalised plans for tapering off opioids. These guidelines are a pivotal advancement in Australia's battle against the opioid epidemic, providing a strategic framework for individuals to safely reduce their opioid dependence. The guidelines emphasise the importance of informed consent, recommending that patients be thoroughly educated about the benefits and risks of opioid therapy before initiating treatment. This includes obtaining written and signed consent, combined with a "treatment agreement" or "opioid contract," as advised by Australian guidelines and mandated by some state governments.
The Australian government's initiatives extend beyond consent procedures. They have also implemented the National Real Time Prescription Monitoring (RTPM) program, enabling healthcare providers to access patients' prescription histories in real time. This tool assists in identifying potential misuse or over-prescription of opioids and other controlled substances. Furthermore, the government has proposed reforms and conducted public consultations to gather insights on potential actions for the TGA to undertake, aiming to reduce inappropriate use and misuse of prescription opioid products.
While the Australian government has made notable strides, the opioid problem persists, resulting in adverse health outcomes and preventable deaths. Tasmania, in particular, has been dubbed the "epicenter" of the country's opioid crisis, with the highest rate of opioid packs sold per person. The situation in Tasmania underscores the urgency of continued efforts to address opioid misuse and the importance of implementing effective harm reduction strategies.
Converting Pounds to Australian Dollars: 2500 and Counting
You may want to see also
Explore related products
The Australian government is working to implement safer, evidence-based pain management strategies
One approach that the government is taking is the introduction of real-time prescription monitoring (RTPM) to provide medical practitioners and pharmacists with individualised prescription data on opioid dispensing. This will help identify cases of overprescribing and reduce the number of opioids in the community that can be misused or abused. Additionally, the government is considering reducing the pack sizes of opioids to prevent unused opioids from being used inappropriately or becoming targets for theft.
The Therapeutic Goods Administration (TGA) has also established the Opioid Regulatory Advisory Group (ORAG) to provide independent, expert advice on regulatory actions to reduce opioid misuse while ensuring that patients can continue to access opioids safely and appropriately. The TGA has also proposed increasing health professional awareness of alternatives to opioids for chronic pain management, such as non-pharmacological and alternate pharmacological therapies.
Furthermore, the government is working to address the underlying causes of opioid misuse and abuse. This includes promoting education on the quality use of opioids and raising awareness about opioid-related problems through various organisation-based websites and position statements. For example, the NSW Agency for Clinical Innovation's Pain Management Network provides information to consumers and health professionals on managing chronic pain. Additionally, Scriptwise, a not-for-profit organisation, aims to prevent the extra-medical use of prescription medications and overdose fatalities in Australia.
The Australian government is also considering implementing and evaluating a direct-to-patient educational approach to empower Australians to make informed decisions about their opioid use. This approach has been trialled in Canada and found to be particularly effective for males, those aged under 65, or those living in urban areas.
Applying to Monash University: A Step-by-Step Guide
You may want to see also
Frequently asked questions
The opioid epidemic in Australia is a result of the increasing use of and harm from prescription opioids. In 2016, around 11% of Australians aged 14 and over had used at least one type of opioid for non-medical purposes. Tasmania is the country's epicentre for opioids, with the highest rate of opioid packs sold per person.
The Australian government has taken several initiatives to address the opioid epidemic, including:
- Asking the Therapeutic Goods Administration (TGA) to play a role in tackling the problem.
- Conducting a public consultation on potential actions and activities the TGA could undertake to mitigate the risks of inappropriate use and misuse of prescription opioid products.
- Implementing reforms that are consistent with actions taken by other medicines regulators such as the FDA and Health Canada to reduce prescription opioid misuse.
- The National Real Time Prescription Monitoring (RTPM) program.
While the Australian government has taken steps in the right direction, more action is needed to address the country's opioid problem. Some potential solutions include:
- Implementing a comprehensive and coordinated approach to overdose prevention by national and state governments and professional groups.
- Empowering Australians to make informed decisions about their opioid use through a direct-to-patient educational approach.
- Creating personalised plans to help people safely taper off opioids.
